CellCentric Secures $60 Million to Advance Clinical Testing of Novel Cancer Therapy
核心洞察
CellCentric (搜索) has raised $60 million in funding to finalize clinical testing, aligning with FDA requirements before initiating Phase III trials.
The funding includes the conversion of a loan note from Pfizer into $25 million equity and an additional investment from BrightEdge, the American Cancer Society’s impact investment arm.
The company's research is based on the epigenetic research of Professor Azim Surani, focusing on epigenetic code beyond DNA to instruct cell fate.
CellCentric (搜索), a company co-founded with epigenetic research pioneer Professor Azim Surani of the Gurdon Institute, University of Cambridge, has secured $60 million in funding to advance the clinical testing of its novel cancer (搜索) therapy. The funding round includes the conversion of a loan note from Pfizer into $25 million equity, alongside a new investment from BrightEdge, the American Cancer Society’s impact investment and innovation arm.
The investment will enable CellCentric (搜索) to complete the necessary clinical testing to meet FDA requirements in preparation for Phase III trials. Professor Surani's work focuses on the discovery and description of an epigenetic code, which exists beyond DNA and can dictate cell fate. This foundational research underpins CellCentric's therapeutic approach.
CellCentric (搜索) aims to leverage its understanding of epigenetic mechanisms to develop targeted cancer (搜索) therapies. The company has not disclosed specific details about the drug or its target, but the funding will be crucial in advancing its clinical development program.